Advances of the Nanotechnology in Targeted Nanomedicines for Treatment of Bone Cancers and Diseases
DOI:
https://doi.org/10.30683/1929-2279.2021.10.05Keywords:
Nanotechnology, Nanomedicine, Nanodrugs, Bone Cancer, Osteosarcoma, Bone Infection, Osteoarthritis, Targeted Delivery.Abstract
The ever-evolving field of nanotechnology has been applied over the years as an amazing potential tool in bone disorders through the development of targeted drug nanosystems. Bone diseases can be referred as any bone condition able to cause morbidity or even mortality to the host. Osteosarcoma has been most investigated condition for management and treatment by nanomedicine, and several nanomaterials such as nanoparticles, nanocapsules, nanospheres, nanodiamonds are being used for drug delivery. Likewise, other bone diseases, such as osteoporosis, osteonecrosis, osteoarthritis, bone tuberculosis have received nanotherapy with a large rate of success. The nanomedicine seems to make up a targeting lack by conventional therapy and chemotherapy, besides appointing to a trend of conservative clinical treatment, especially for severe disorders. Additionally, nanomedicine has advanced over the years, therefore, there is a strong need to accelerate its application in bone diseases reducing the mortality rate related to these conditions. This review article provides an overview on the advances of nanotechnology over the last two decades and highlights the pathways of investigations for targeted delivery nanoensembles.
Downloads
Published
Issue
Section
How to Cite
Similar Articles
- Jia-Jie Shi, Ling-Hua Meng, Autophagy in Cancer Therapy: Progress and Issues , Journal of Cancer Research Updates: Vol. 4 No. 1 (2015)
- Pedro Cuevas, Javier Angulo, Adrián Cuevas-Bourdier, Guillermo Giménez-Gallego, Topical Treatment of Skin Squamous Cell Carcinoma with Potassium Dobesilate Cream , Journal of Cancer Research Updates: Vol. 1 No. 1 (2012)
- Hossam M.M. Arafa, Raed S. Ismail, Nesreen Nabil, Adel M. Mostafa, Carnitine Deficiency: A Causative Clue or a Sequel in Carboplatin Myelosuppression , Journal of Cancer Research Updates: Vol. 3 No. 4 (2014)
- Jian-Yang Hu, Min-Feng Chen, Xue-Ping Lei, Zhen-Jian Zhuo, Hai-Yan Sun, Zhe-Sheng Chen, Zhi Shi, Dong-Mei Zhang, Wen-Cai Ye, Bufalin Induces Apoptosis of MDA-MB-231 Cell Through Activation of JNK/p53 Pathway , Journal of Cancer Research Updates: Vol. 4 No. 2 (2015): Special Issue - Natural Products for Cancer Prevention and Treatment
- Edwin F. Crandley, David D. Wilson, Austin J. Sim, Neil Majithia, Edward B. Stelow, Mark J. Jameson, David C. Shonka Jr., Asal S. Rahimi, Paul W. Read, Patterns of Distant Failure and Second Primary Cancers in Patients with Oropharyngeal Squamous Cell Carcinoma: Implications for Surveillance Methodology , Journal of Cancer Research Updates: Vol. 3 No. 3 (2014)
- Igor V. Maev, Dmitry N. Andreev, Yuriy A. Kucheryavyy, Diana T. Dicheva, Neuroendocrine Tumors of the Pancreas: Molecular Pathogenesis and Perspectives on Targeted Therapies , Journal of Cancer Research Updates: Vol. 3 No. 3 (2014)
- Tchin Darré, Lantam Sonhaye, Mazamaesso Tchaou, Kokou Kanassoua, Abdoulatif Amadou, Aklesso Bagny, Alphonse Aman N’Guiessan, Koffi Amegbor, G. Napo-Koura, Histo-Epidemiological Profile of Digestive Cancers in Togo , Journal of Cancer Research Updates: Vol. 4 No. 3 (2015)
- Lydia Hopp, Edith Willscher, Henry Löffler-Wirth, Hans Binder, Function Shapes Content: DNA-Methylation Marker Genes and their Impact for Molecular Mechanisms of Glioma , Journal of Cancer Research Updates: Vol. 4 No. 4 (2015)
- Teoh Han Pinn, Siti Fathiah Masre, Nadiah Abu, MiR-130b-3p Suppress the Migration, Proliferation and Chemosensitization of Hepatocellular Carcinoma Cells , Journal of Cancer Research Updates: Vol. 13 (2024)
- Amy Zhong, Melissa Chang, Theresa Yu, Raymond Gau, Daniel J. Riley, Yumay Chen, Phang-Lang Chen, Aberrant DNA Damage Response and DNA Repair Pathway in High Glucose Conditions , Journal of Cancer Research Updates: Vol. 7 No. 3 (2018)
You may also start an advanced similarity search for this article.